Processa Pharmaceuticals, Inc. (PCSA) Initiation Report

October 28, 2020 Processa Pharmaceuticals, Inc. Page 14 of 16 ALPHA SELECT LIST Institutional Research Sian Bigora, Pharm.D., Chief Development Officer. Dr. Bigora has over 20 years of pharmaceutical research, regulatory strategy and drug development experience working closely with Dr. Young. She was Co-Founder, Director, and Chief Development Officer at Promet Therapeutics; Vice President of Regulatory Affairs at Questcor from 2009-2015, including leading efforts on modernizing the Acthar Gel label, obtaining FDA approval in Infantile Spasms, and building an expert regulatory group. Dr. Bigora's role at Questcor included heading up the development of a safety pharmacovigilance group and a clinical quality group. Prior to Questcor, Dr. Bigora was VP of Clinical and Regulatory Affairs, U.S. Operations of AGI Therapeutics, plc. Dr. Bigora previously held multiple positions in regulatory affairs, operations and project management ending as VP of Regulatory Affairs at the Strategic Drug Development Division of ICON and GloboMax. Prior to GloboMax, she worked in the Pharmacokinetics and Biopharmaceutics Laboratory at the School of Pharmacy, University of Maryland on the FDA funded Clinical Pharmacology contract and UMAB-FDA contract as a clinical scientist and instructor for FDA reviewers. Dr. Bigora received a Pharm.D. from the School of Pharmacy at the University of Maryland at Baltimore. She also completed a Fellowship in Pharmacokinetics and Pediatric Infectious Diseases at the University of Maryland at Baltimore. Patrick Lin, Chief Business - Strategy Officer. Mr. Lin has over 20 years of financing and investing experience in biopharma. He is Founder and Managing Partner of Primarius Capital; was Co-Founder and Chairman of the Board of Promet Therapeutics; was Co-Founding Partner of E*Offering; and part of several other Wall Street banking and brokerage firms including Robertson Stephens & Co. and Goldman Sachs & Co. Mr. Lin received an MBA from Kellogg Graduate School of Management, a Master of Engineering Management, and a Bachelor of Science in Business Administration from the University of Southern California. Michael Floyd, Chief Operating Officer. Mr. Floyd is a serial entrepreneur who, over the last 15 years, has formed and been a senior executive in several life science organizations focused on the development of products to treat infectious and rare diseases, as well as the development of oncology drugs. He founded the early stage enterprise Neurologic, that in-licensed technology from the NIH for a diagnostic test for Alzheimer’s disease. In 2006 he served as the CEO for the North American subsidiary of Arpida Ltd. and organized the Phase III program for the NDA submission of an MRSA drug. Then after joining Gentium, SpA in 2011, he led the US efforts to remediate the NDA for defibrotide. More recently, Mr. Floyd co-founded Elion Oncology which licensed PCS6422 to Processa. James Stanker, CFO. Mr. Stanker has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016. Prior to joining Grant Thornton, Mr. Stanker served as the Chief Financial Officer for a NASDAQ listed company and for a privately-held life science company. Mr. Stanker is a Certified Public Accountant. He has a bachelor's degree in Aeronautics from San Jose State University and a Master's in Business Administration from California State University, East Bay.